Antifungal chemoprophylaxis after blood and marrow transplantation

Clinical Infectious Diseases

Volumn 34, Issue 10, 2002, Pages 1386-1390

  Wingard, John R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; BONE MARROW TRANSPLANTATION; CHEMOPROPHYLAXIS; HUMAN; MYCOSIS; PRIORITY JOURNAL; TREATMENT FAILURE;

ANTIFUNGAL AGENTS; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CANDIDA; CANDIDIASIS; CHEMOPREVENTION; FLUCONAZOLE; FORECASTING; HUMANS;

EID: 0037093952     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/340263     Document Type: Article

References (32)

1. An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis
2. Antifungal prophylaxis during neutropenla or allogeneic bone marrow transplantation: What is the state of the art?
3. Prevention of fungal sepsis in patients with prolonged neutropenia: A randomized, double-blind, placebo-controlled trial of intravenous miconazole
4. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia
5. Empiric antifungal therapy in febrile granulocytopenic patients
6. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
7. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - A prospective, randomized, double-blind study
8. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy
9. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with hematological malignancies and bone marrow transplant recipients
10. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial
11. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
12. Fluconazole vs. low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: A study of the North American Marrow Transplant Group
13. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: Recommendations of the Centers for Disease Control and Prevention, the Infectious Diseases Society of America, asnd the American Society of Blood and Marrow Transplantation
14. Fluconazole to prevent yeast infections in bone marrow transplantation patients: A randomized trial of big versus reduced dose, and determination of the value of maintenance therapy
15. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis: An autopsy study of 355 patients
16. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole
17. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients
18. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole
19. Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: A randomized trial in bone marrow transplant recipients
20. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: A randomized, double-blind, placebo-controlled study
21. Antifungal prophylaxis in patients with hematologic malignancies: A reappraisal
22. The value of fungal surveillance cultures as predictors of systemic fungal infections
23. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation
24. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients
25. Late onset of invasive Aspergillus infection in bone marrow transplant patients at a university hospital
26. Aspergillosis in HSCT recipients: Evidence for two distinct pathophysiologic conditions associated with engraftment status
27. Screening for circulating galactomannan as a non-invasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: A prospective validation
28. Utility of galactomannan detection for the diagnosis of invasive aspergillosis in HSCT recipients
29. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: A randomized, controlled trial
30. Long-term antifungal prophylaxis in altogeneic bone marrow transplant patients: A mufti-center, randomized trial of intravenous/oral itraconazole versus intravenous/oral fluconazole
31. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever
32. Open, randomized comparison of voriconazole (VRC) and amphotericin B (AmB) followed by other licensed antifungal therapy (OLAT) for primary therapy of invasive aspergillus (IA)